- IMMUNO-FIT Observational Study — Recruiting • Oncology • NCT07354971.
- What is being tested: The study investigates how immunotherapy (checkpoint inhibitors) affects physical fitness, quality of life, and treatment tolerance in adults with solid tumours, capturing real-world impacts on daily functioning beyond standard safety monitoring.
- Patient eligibility: Adults aged ≥18 years with solid cancers commencing immunotherapy treatment are eligible; the observational design allows inclusion across diverse cancer types and treatment settings without restrictive exclusion criteria.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers. Immunotherapy can cause a range of side effects that impact daily functioning and may lead to treatment delays or early discontinuation. Physical fitness may influence how well patients cope with treatment, yet little is known about how fitness changes during immunotherapy or whether baseline fitness is linked to outcomes. Participants will complete fitness testing using cardiopulmonary exercise testing (CPET) and quality-of-life questionnaires before starting immunotherapy and again 12 weeks…
- : * Age ≥18 years * Histologically confirmed solid malignancy * Receiving immune checkpoint inhibitors in one of the following settings: * Adjuvant: Single-agent anti-PD-1, anti-PD-L1, or anti-CTLA-4 * Metastatic/Palliative: Single-agent or dual-agent anti-PD-1, anti-PD-L1, or anti-CTLA-4 * ECOG Performance Status 0-2 * Able to perform cardiopulmonary exercise testing * Able to provide written informed consent * Willing and able to comply with study procedures and follow-up schedule
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.